The effect of peripheral blood eosinophil/lymphocyte ratios on chemotherapy response and prognosis before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Year 2026, Volume: 40 Issue: 1, 51 - 64, 28.01.2026

Öykü Ünsal

https://doi.org/10.18614/dehm.1873599

Abstract

ABSTRACT
BACKGROUND
This study aims to examine the peripheral blood eosinophil/lymphocyte ratio (ELR) as a simple, affordable and easily accessible marker to predict neoadjuvant chemotherapy (NACT) response and prognosis in patients with locally advanced breast cancer (LABC).
METHODS
The study included 102 female patients over the age of 18 who were diagnosed with LABC in 2010-2019 and were treated with NACT at Dokuz Eylül University Faculty of Medicine, Department of Internal Medicine, Medical Oncology. The patients were retrospectively examined for demographic, clinical, pathological and laboratory data. Laboratory data (leukocyte count, eosinophil count and percentage, lymphocyte count and percentage, ELR and eosinophil x lymphocytes) were evaluated before chemotherapy, before surgery and before relapse. Single and multi-variable regression analyses were performed to determine risk factors important for pathological complete response (pCR) and relapse development. The Kaplan-Meier survival analysis method was used to determine the effects of these factors on PFS (progression-free survival).
RESULTS
The mean diagnostic age was 50.8±13.0 years, the follow-up time was 41.0±27.0 months, and the average time from NACT to operation was 7.9±2.5 months. Mortality rate was 10.8%, relapse rate was 14.7%, and PCR incidence rate was 27.5%. No statistically significant differences were found in the ELR and eosinophil x lymphocyte parameters before and after NACT in terms of their value in pCR and relapse prediction. The most important predictive clinical and pathological features for pCR were found to be low count of positive lymph nodes (LN) (OR = 0.342, p = 0.04) and ER negativity (OR = 2.6, p = 0.035). The risk of recurrence in patients with a positive LN count of three and above was 3.8 times greater (OR = 3.8, p = 0.008) and the duration of PFS was shorter. The risk of recurrence in patients with a pre-NACT lymphocyte percentage of 26.75 and below was 4.2 times greater (OR = 4.2, p = 0,016), and the duration of PFS was shorter.
CONCLUSION
The study suggests that if more patients are evaluated and over a long follow-up period, markers such as peripheral blood ELR or eosinophil x lymphocyte could be used as affordable, easily accessible predictive and prognostic markers for predicting NACT response.

Keywords

Locally advanced breast cancer , neoadjuvant chemotherapy , pathological complete response , prognostic marker , recurrence

References

• 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
• 2. Türkyılmaz M, Öztürk M, Dündar S. Türkiye Kanser İstatistikleri. T.C. Halk Sağlığı Kurumu Ankara. 2017. 75–77 p.
• 3. Güler N, Karabulut B, Koçdor MA. Lokal İleri Meme Kanseri 2010 İstanbul Konsensus Toplantısı. J Breast Heal. 2011;7(2):68–89.
• 4. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
• 5. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22;321(3):288–300.
• 6. Barni S, Mandalà M, Williams L, Barni S. Locally advanced breast cancer. Curr Opin Obstet Gynecol. 2006;18:47–52.
• 7. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017 Jan 5;19(1):1–13.
• 8. Simon RM, Paik S HD. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–1452.
• 9. Eren T, Karacin C, Ucar G, Ergun Y, Yazici O, İmamoglu İ, et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients. Medicine (Baltimore). 2020 May 29;99(22):e20346.
• 10. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
• 11. Weller PF, Lim K. Human Eosinophil-Lymphocyte Interactions. Mem Inst Oswaldo Cruz, Rio Janeiro. 1997;92:173–82.
• 12. Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in Cancer: Favourable or Unfavourable? Curr Med Chem. 2016 Jan 20;23(7):650–66.
• 13. Balkwill FR, Mantovani A. Cancer-related inflammation: Common themes and therapeutic opportunities. Semin Cancer Biol. 2011;22:33–40.
• 14. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ et all. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015 May 19;16(6):609–17.
• 15. Omranipour R, Jalili R, Yazdankhahkenary A, Assarian A, Mirzania M, Eslami B et all. Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR. Eur J breast Heal. 2020 Jun 24;16(3):213–8.
• 16. Simos D, Clemons M, Ginsburg OM, Jacobs C. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8(1):33–8.
• 17. Iwamoto N, Aruga T, Horiguchi S, Saita C, Onishi M, Goto R, et al. Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy. Surg Today. 2020 Feb 1;50(2):178–84.